Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice

Basit Öğe Kaydı
dc.authorid0000-0003-0230-6575
dc.authorid0000-0003-2714-4584
dc.authorid0000-0002-4281-0867
dc.authorid0000-0003-2995-8792
dc.authorid0000-0003-1919-3183
dc.authorid0000-0001-5825-8627
dc.authorid0000-0003-1516-1811
dc.authorid0000-0002-4951-6716
dc.contributor.authorÇakal, Beytullah
dc.contributor.authorÇakal, Sinem Deniz
dc.contributor.authorKaraca, O?uz
dc.contributor.authorOmaygenç, Mehmet Onur
dc.contributor.authorKızılırmak, Filiz
dc.contributor.authorGüneş, Hacı Murat
dc.contributor.authorÖzcan, Özgür Ulaş
dc.contributor.authorİbişoğlu, Ersin
dc.contributor.authorBoztosun, Bilal
dc.date.accessioned2021-04-05T12:15:56Z
dc.date.available2021-04-05T12:15:56Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractBACKGROUND: Most of the current data regarding the use of bioresorbable scaffolds (BRS) come from everolimus-eluting stent platforms. Adverse events with the everolimus-eluting BRSs which are the most comprehensively characterized BRS, hampered the clinical use of other BRS. There is paucity of published data regarding long term use of novolimus-eluting BRS.METHODS: This study sought to evaluate the performance of novolimus-eluting BRS device at midterm follow-up in real world clinical practice. One hundred and forty four patients (mean age 57.5 ± 9.7 years, 78.5% male) treated with 206 scaffolds between October 2015 and December 2017 were enrolled. A device-oriented composite endpoint (DOCE) comprising cardiac death, target vessel myocardial infarction (TV-MI), clinically driven target lesion revascularization (TLR) and rate of scaffold thrombosis were investigated.RESULTS: During a mean follow-up of 33±9 months, DOCE occured in 9 patients (6.3%) of which cardiac death occured in 2 patients (1.4%), and clinically-driven TLR in 7 patients (4.9%), TV-MI in one patient. Target vessel revascularization (TVR) was observed in nine patients. None of the patients experienced scaffold thrombosis.CONCLUSIONS: The use of novolimus-eluting BRS in this real world population achieved good clinical outcomes.
dc.identifier.citationÇakal, B., Çakal, S. D., Karaca, O., Omaygenç, M. O., Kızılırmak, F., Güneş, H. M. ... Boztosun, B. (2021). Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice. Minerva Cardioangiologica, 69(3), 261-268. https://dx.doi.org/10.23736/S0026-4725.20.05138-5
dc.identifier.doi10.23736/S0026-4725.20.05138-5
dc.identifier.endpage268
dc.identifier.issn0026-4725
dc.identifier.issn1827-1618
dc.identifier.issue3
dc.identifier.scopusqualityN/A
dc.identifier.startpage261
dc.identifier.urihttps://dx.doi.org/10.23736/S0026-4725.20.05138-5
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6695
dc.identifier.volume69
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherEdizioni Minerva Medica
dc.relation.ispartofMinerva Cardioangiologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBioresorbable Vascular Scaffold
dc.subjectPercutaneous Coronary Intervention
dc.subjectMajor Cardiac Events
dc.titleOutcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu